Unraveling cocaine metabolism in patients with cocaine use disorder for the purpose of potentially improving bioanalytical tests for cocaine use - Unraveling cocaine metabolism in patients with CUD

Start Date12 Nov 2024

Sponsor / Collaborator-

NCT06443255 / CompletedPhase 3IIT

Comparison of Cocaine, Lidocaine/xylometazoline and Saline for Intranasal Analgesia - a Blinded Triple Crossover Study

When performed by trained personnel nasotracheal intubation is a safe and effective technique for attaining a secure airway in preparation for surgery of the head and neck. The procedure can be deemed necessary due to the nature of the surgical procedure or considerations in regard to the patient's comorbidities. For a certain group of patients with expected difficult airways, the procedure is done whilst they are awake and aided by fiberoptics.
For these awake patients, extra precautions must be taken to ensure the procedure is conducted with minimal pain and discomfort. The pain and discomfort arises from the mechanical manipulation of the nasal mucosa and can be alleviated in part by means of topical analgesia as well as through decongestion, providing more space within the nasal cavity. For these purposes, several drugs in varying combinations and dosages are used, but no single drug choice is universally recommended.
Cocaine is one of these appropriate drugs. It is a magistral formula used especially due to its unique combination of both vasoconstrictive and analgesic properties. Concerns have though been raised regarding cocaine's potential toxicity and alternative medications are continuously sought after.
A combination of lidocaine and xylometazoline can also be used for preparation of the nose prior to awake nasal fiberoptic intubation. Lidocaine contributes with its analgesic effect whilst xylometazoline functions as the vasoconstrictor.
The investigators wish to compare the analgesic effects of cocaine and lidocaine/phenylephrine to each other and saline when subjectively scored on a visual analogue scale of 0-100 mm immediately after simulated awake nasal intubation on healthy volunteers.

Start Date01 Jul 2024

Sponsor / Collaborator

Rigshospitalet

NCT05809453 / CompletedPhase 1/2IIT

Intranasal Cocaine and Temperature Regulation During Exercise

Assess the effects of intranasal cocaine on temperature regulation and whole-body sweat rate during exercise in warm environmental conditions.

Start Date01 Sep 2023

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

100 Clinical Results associated with Cocaine Hydrochloride

100 Translational Medicine associated with Cocaine Hydrochloride

100 Patents (Medical) associated with Cocaine Hydrochloride

37,327

Literatures (Medical) associated with Cocaine Hydrochloride

01 Mar 2025·NEUROPHARMACOLOGY

Astrocytic regulation of cocaine locomotor sensitization in EcoHIV infected mice

Article

Author: Park, Kyewon ; Xie, Qiaowei ; Side, Christine M ; Buck, Lauren A ; Jackson, Joshua G ; Namba, Mark D ; Barker, Jacqueline M ; Dasari, Rohan

Cocaine use disorder (CUD) is highly comorbid with HIV infection and worsens HIV outcomes. Preclinical research on the outcomes of HIV infection may yield crucial information on neurobehavioral changes resulting from chronic drug exposure in people living with HIV (PLWH). Repeated exposure to cocaine alters behavioral responses to cocaine. This includes development of cocaine locomotor sensitization - or increased locomotor responses to the same doses of cocaine - which depends on nucleus accumbens (NAc) neural plasticity. NAc astrocytes are key regulators of neural activity and plasticity, and their function can be impaired by cocaine exposure and HIV infection, thus implicating them as potential regulators of HIV-induced changes in behavioral response to cocaine. To characterize the effects of HIV infection on cocaine locomotor sensitization, we employed the EcoHIV mouse model in male and female mice to assess changes in locomotor responses after repeated cocaine (10 mg/kg) exposure and challenge. EcoHIV infection potentiated expression of cocaine sensitization. We also identified EcoHIV-induced increases in expression of the astrocytic nuclear marker Sox9 selectively in the NAc core. To investigate whether modulation of NAc astrocytes could reverse EcoHIV-induced deficits, we employed a chemogenetic approach. We found that chemogenetic activation of NAc astrocyte Gq signaling attenuated EcoHIV-enhanced cocaine sensitization. We propose that HIV infection contributes to cocaine behavioral sensitization and induces adaptations in NAc astrocytes, while promoting NAc astrocytic Gq-signaling can recover EcoHIV-induced behavioral changes. These findings identify potential cellular substrates of disordered cocaine-driven behavior in the context of HIV infection and point toward strategies to reduce cocaine-related behavior in PLWH.

01 Feb 2025·TALANTA

Construction of fluorescent biosensor based on aptamer recognition and enzyme-free nucleic acid signal amplification reaction and its application in cocaine detection

Article

Author: Li, Quanfang ; Zhang, Yuan ; Ma, Chen ; Ren, Shufang ; Wei, Shuoyun

Cocaine is a white crystalline alkaloid extracted from coca leaf. It can block human nerve conduction, produce local anesthetic effect, and has strong addiction. Therefore, the qualitative and quantitative analysis of cocaine is of great significance in forensic toxicology, pharmacy and metabolomics. Cocaine aptamer probe is expected to become a powerful tool for on-site detection of cocaine due to its good stability, fast response speed, and easy preparation of kits for on-site application. In our work, we construct a fluorescent biosensor for the detection of cocaine by using the characteristics of specific binding of nucleic acid aptamers to targets and combining with enzyme-free nucleic acid signal amplification reaction. First, streptavidin-modified magnetic beads (MBs) can specifically bind to biotin-modified cocaine aptamer probe (Aptamer) to form MB-DNA. The nucleic acid aptamer complementary probe (tDNA) can hybridize with the aptamer through base complementary pairing to form a double strand, thereby obtaining the MB-DNA-tDNA complex. When cocaine is present in the system, cocaine specifically binds to aptamer, thereby replacing the probe tDNA. The probe tDNA can undergo hybridization chain reaction with the hairpin probe 1 (HP1) and hairpin probe 2 (HP2), resulting in the opening of the hairpin structure, and the fluorescence signal response of the fluorophore 6-carboxyfluorescein (FAM) modified on the HP1 is turned on, so as to achieve rapid, low-cost and efficient cocaine detection. The establishment of this method can enrich and develop the basic theory of drug analysis and detection, and provide theoretical guidance and technical support for the accurate, efficient and convenient detection of drug analysis methods on site.

01 Feb 2025·PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Long- vs short-access cocaine alters behavioral inhibition for cocaine in male rats

Article

Author: Hanson, Taena ; Stairs, Dustin J

Impulsivity and behavioral inhibition are measures commonly associated with substance misuse, particularly cocaine use disorder. However, patterns of impulsive behaviors have been shown to differ based on cocaine use history and level of cocaine dependence. Extended cocaine access, which more closely models neural and behavioral changes that take place during the development of problematic cocaine use, has been shown to decrease behavioral inhibition in comparison to limited cocaine access. However, previous preclinical studies investigating these relationships have been mostly correlational and only utilize non-drug rewards. This study aims to utilize a differential rates of low reinforcement (DRL) schedule to investigate the impact of extended access to cocaine on behavioral inhibition toward a cocaine reinforcer. Male Sprague Dawley rats first self-administered intravenous cocaine infusions on a DRL schedule of reinforcement before being split into two groups: one given 6-h extended cocaine access (LgA) and one given 1-h short cocaine access (ShA) for 10 daily sessions. Following a washout period, the rats were placed back on DRL cocaine self-administration sessions. Results revealed that LgA rats showed impaired performance on the behavioral inhibition measure during the DRL self-administration sessions compared to baseline DRL performance and compared to ShA post-access behavioral inhibition measures. These results indicate that extended cocaine access impairs an organism's behavioral inhibition toward future cocaine use, indicating that those individuals with a history of heavy cocaine use will have impaired behavioral inhibition toward future cocaine use.

190

News (Medical) associated with Cocaine Hydrochloride

26 Nov 2024

·www.globenewswire.com

Intelligent Bio Solutions Achieves 94.1% Accuracy in Method Comparison Study, Following Positive PK Study Results

Intelligent Fingerprinting Drug Screening System on path to FDA 510(k) submission, expected in the fourth calendar quarter of 2024 INBS will include data from recent PK study alongside results of method comparison study in 510(k) submission NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of its method comparison study (the “Method Study”) on its Intelligent Fingerprinting Drug Screening System (the “System”). The Method Study confirmed the sensitivity, specificity, accuracy, and usability of the System, validating its potential for use in workplace drug testing and other applications. This milestone follows INBS’ recently announced strong initial results from its Pharmacokinetic (PK) study, both of which are key achievements on the path to the Company’s FDA 510(k) submission. The Method Study was conducted in collaboration with CenExel, a nationwide clinical research site network. It adhered to clinical research standards, including Good Clinical Practice (GCP) guidelines. The Method Study's primary objective was to compare the results of fingerprint sweat opiate screening tests with those obtained using a validated, traceable liquid chromatography-mass spectrometry (LC-MS/MS) method in a laboratory. With a diverse group of 135 healthy donors and nine system operators, the Method Study demonstrated 82.2% sensitivity, 100% specificity, and 94.1% accuracy for the Intelligent Fingerprinting Drug Screening System. Operators found the System easy to use, with no usage errors generated during the course of the study. “The results of our Method Study reaffirm the accuracy and reliability of our fingerprint-based drug screening system,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “By establishing alignment with laboratory-confirmed results through rigorous testing, we have solidified our drug screening system’s credibility for use in safety-critical industries and beyond. This accomplishment is a significant step on our journey toward transforming drug testing with non-invasive technology.” The Method Study evaluated the System’s three core components: the Drug Screening Cartridge, the Drug Screening Reader and the Fingerprint Collection Kit for laboratory analysis. Subjects were randomized and administered codeine doses, then provided fingerprint sweat specimens to assess the System's ability to detect and quantify drug use accurately. The Method Study’s outcomes highlight the System’s reliability, reinforcing its suitability for pre-employment and workplace drug testing applications. If FDA 510(k) clearance were obtained, INBS believes that this would pave the way for the Company to introduce its innovative fingerprint sweat-based drug screening technology to the US market in 2025. As part of the Company's 510(k) submission, which is expected in the fourth calendar quarter of this year, INBS will include data from its recently concluded PK study alongside the results of its Method Study. The Company's clinical study achievements show the accuracy, reliability, and usability of its technology and reinforce the Company's readiness to address the growing demand for drug testing in the US across safety-critical industries such as construction, mining, and transportation, as well as in the law enforcement, drug rehabilitation, and forensic sectors. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. For more information, visit: http://www.ibs.inc/ Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact:Intelligent Bio Solutions Inc.info@ibs.incLinkedIn | Twitter Investor & Media Contact:Valter Pinto, Managing DirectorKCSA Strategic CommunicationsPH: (212) 896-1254INBS@kcsa.com

Clinical Result

21 Nov 2024

·www.globenewswire.com

Intelligent Bio Solutions to Participate in the Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present at the upcoming Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference on December 3-4, 2024, in Boca Raton, FL. Noble Capital Markets’ 20th Annual Emerging Growth Equity ConferenceDates: December 3-4, 2024Location: Florida Atlantic University, Boca Raton, FLPresentation Day and Time: Wednesday, December 4, 2024, at 2:00 p.m. ET Presentation Location: Presentation Room 3 A link to the recording of the presentation will be available on INBS’s Investor Relations website two days after the event. Management will also be available during the event for one-on-one meetings with the investment community. To schedule a meeting, please contact your NobleCon representative or KCSA Strategic Communications by emailing INBS@kcsa.com. About Intelligent Bio Solutions Inc.Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. For more information, visit: http://www.ibs.inc/ Company Contact: Intelligent Bio Solutions Inc. info@ibs.inc Investor & Media Contact: Valter Pinto, Managing Director KCSA Strategic Communications PH: (212) 896-1254 INBS@kcsa.com

13 Nov 2024

·www.globenewswire.com

Intelligent Bio Solutions Announces Positive Results of PK Study, a Key Milestone on Path to FDA 510(k) Submission

PK Study Successfully Demonstrates that Fingerprint Sweat Provides Reliable Sample for Drug Detection FDA 510(k) Clearance Would Enable the Introduction of INBS’ Technology to the US in 2025 NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced strong initial results from its Pharmacokinetic (PK) study required for an FDA 510(k) submission. The data from the PK study shows that fingerprint sweat mimics the rate and extent of codeine in blood and saliva. The study successfully demonstrated that fingerprint sweat provides a reliable sample matrix for drug detection, showing quantitative PK data closely aligned to blood, based on statistical comparisons made at the 95% confidence level. "The close correlation of PK parameters in fingerprint sweat and blood highlights its robustness as a sampling approach. While independent data has consistently supported this, our clinical study further reinforces these findings,” said Harry Simeonidis, President and CEO of Intelligent Bio Solutions. “We are very pleased with the PK study results. This data highlights the potential for our technology to achieve widespread adoption in safety-critical industries and beyond, marking a significant achievement as we advance toward FDA clearance in the United States." FDA 510(k) clearance would enable INBS to introduce its innovative drug screening technology to the US market in 2025. The PK study results and other clinical data from the Company's clinical study plan will be submitted as part of the Company's 510(k) submission, expected in the fourth calendar quarter of this year. INBS is well-positioned to meet the increasing demand for drug testing in the United States, particularly in safety-critical industries like construction, mining, and transportation, as well as in law enforcement, drug rehabilitation, and forensic sectors. Results: Average Codeine Values in Whole Blood, Oral Fluid and Fingerprint Sweat1 The study results show that fingerprint sweat is a strong indicator of codeine ingestion. They further validate the ability of INBS' method to provide rapid and reliable drug screening through a simple fingerprint sweat sample without invasive procedures. The PK study, conducted in partnership with Cliantha Research, required a minimum of 36 subjects. The Company successfully recruited 39 healthy adult subjects from diverse backgrounds, including varying genders, ages, and ethnicities. The study compared the levels of opiates detected in fingerprint sweat with those found in blood, oral fluid, and urine samples following the medically supervised administration of codeine. All fingerprint sweat specimens collected using INBS' Intelligent Fingerprinting Drug Screening System, were analyzed by a validated, traceable liquid chromatography/tandem mass spectrometry (LC-MS/MS) method, widely accepted as the gold standard for such studies. About Intelligent Bio Solutions Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. For more information, visit: http://www.ibs.inc/ Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact: Intelligent Bio Solutions Inc.info@ibs.incLinkedIn | Twitter Investor & Media Contact: Valter Pinto, Managing DirectorKCSA Strategic CommunicationsPH: (212) 896-1254INBS@kcsa.com 1 Urine results are not included in this chart. Due to the nature of urine sample collection, which depends on an individual's need to urinate, samples cannot be collected at fixed intervals. Therefore, urine specimens were collected on an ad-lib basis as frequently as possible. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6806ebb4-b738-4c65-b0a0-e6a4c1dc9626

Clinical Result

100 Deals associated with Cocaine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02182	Cocaine Hydrochloride	S01HA01 S02DA02 N01BC01	DB00907

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	US	Noden Pharma DACStartup	14 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cocaine-Related Disorders	Phase 2	US	Biotie Therapies Oy	01 Jun 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ATS2024	Not Applicable	-	-	Cocaine	zfzlqatqmw(jxsfgiuhpj) = showed a Wellens' pattern with ST-elevation and biphasic T-waves in lead V2-V3 soffvcruwz (woaxkbvnnc ) View more	-	19 May 2024
P2-4.012 (AAN2024)	Not Applicable	Ischemic stroke	-	Cocaine users	kkvynylwfw(udmvbhwrck) = cwdtmrqcey yxqucykueq (gmlxaopsgj )	Negative	09 Apr 2024
P2-4.012 (AAN2024)	Not Applicable	Ischemic stroke	-	Non-cocaine users	kkvynylwfw(udmvbhwrck) = zqkwkuunmj yxqucykueq (gmlxaopsgj )	Negative	09 Apr 2024
SFN2023	Not Applicable	Cocaine-Related Disorders	-	cocaine (Slc26a7+ cells)	juvnwajqzp(rjeumdkirl) = ocqtrtjaxh bwatcqqbje (azrmztykfe )	-	14 Nov 2023
SFN2023	Not Applicable	-	-	Cocaine self-administration	zlwwalwnzw(wwccshxcmc) = dhfmlacwsz nvykrabgom (kwpuaczkfz )	-	13 Nov 2023
ATS2023	Not Applicable	-	-	Cocaine inhalation	vypeadlldv(gnopxtgepy) = Prevention of pulmonary toxicity requires cessation of cocaine use and a referral to a substance use treatment program is advised. ktmbkbbmvy (fsccxlwshi ) View more	-	21 May 2023
ATS2023	Not Applicable	-	-	Cocaine	jeebkyorng(aekgoggcgh) = fwezxstgtk rqqufsifqv (wbteutmzug ) View more	-	21 May 2023
NCT01906346 (CTgov)	Early Phase 1	Cocaine-Related Disorders	9	Placebo+Cocaine (Low Value Alternative Reinforcer)	adysuakdnn(wuhaidqudw) = eygemcmjeb lbfooknecy (iyrrmbzajp, azvbneentf - vmvbenkspw) View more	-	17 May 2019
NCT01906346 (CTgov)	Early Phase 1	Cocaine-Related Disorders	9	Placebo+Cocaine (Medium Value Reinforcer)	adysuakdnn(wuhaidqudw) = ojkspgbvil lbfooknecy (iyrrmbzajp, tzjerqhlwq - tzoigesuet) View more	-	17 May 2019
NCT02383043 (CTgov)	Early Phase 1	Cocaine-Related Disorders	18	Cocaine+Sustained Release d-Amphetamine	grjjziglzp(vqzqqcrbsq) = aaaewlrtep vwnevvzhhv (qzcsftyeah, nlttzpbsxh - sgpkrcvhan) View more	-	11 Apr 2019
AAN2018	Not Applicable	Acute Ischemic Stroke cocaine use	-	AIS with cocaine use	uxvownrlxx(urcdcqpoyl) = qutqahijfe igjjyvfisl (mupggkowet ) View more	-	10 Apr 2018
AAN2018	Not Applicable	Acute Ischemic Stroke cocaine use	-	AIS without cocaine use	uxvownrlxx(urcdcqpoyl) = vkhagabtgi igjjyvfisl (mupggkowet ) View more	-	10 Apr 2018
SFN2017	Not Applicable	-	-	cocaine (Sham lesion of the mPOA)	tvmqffdtsp(jhljgudtxv) = gzqxbiumzx bykuiyypzj (xbzcorbukm )	-	13 Nov 2017
SFN2017	Not Applicable	-	-	cocaine (Lesion of the mPOA)	tvmqffdtsp(jhljgudtxv) = dfhgsdixfj bykuiyypzj (xbzcorbukm )	-	13 Nov 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis